Recognition of original inception date of existing policy and simplified underwriting questionnaire make it simple and easier for Shield policyholders to switch plans SINGAPORE – […]
OSLO, Norway–(BUSINESS WIRE)–#AI—Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensorsâ„¢ currently deployed in over 500 […]
The Club Members can earn up to 9,000 Clubpoints through designated credit card application via specified website HONG KONG SAR – Media OutReach – 11 […]
KUALA LUMPUR, MALAYSIA – Media OutReach – 11 September 2023 – Kenanga Futures Sdn Bhd (“Kenanga Futures“) proudly announces its latest nationwide initiative, the “Grow […]
Dean Rogers to Oversee Growth After Integration of Recent Compliance Learning Acquisition from Thomson Reuters TOKYO–(BUSINESS WIRE)–LRN Corporation, the leader in ethics and compliance solutions […]
MOSCOW, RUSSIA – Media OutReach – 11 September 2023 – Metalloinvest, a pioneer of green metallurgy in Russia, has opened its enterprises for industrial tourism. […]
SHANGHAI–(BUSINESS WIRE)–The Shanghai office of international law firm Dorsey & Whitney has moved to a new address: CITIC Square, Suite 3707-3708, 1168 Nan Jing West […]
HONG KONG–(BUSINESS WIRE)–#insurance–Despite a sharp increase in catastrophe losses outside their home markets and a challenging investment environment, major Asia-Pacific reinsurance companies still managed to […]
SolarWinds will showcase its product portfolio and speak on how integrated observability and service management solutions help ensure operational resiliency AUSTIN, Texas–(BUSINESS WIRE)–SolarWinds (NYSE:SWI), a […]
ZUG, SWITZERLAND – Media OutReach – 11 September 2023 – pCloud, the leading platform in online storage and data management, proudly commemorates a decade of […]
Today marks 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal antibody biosimilar infliximab, for all indications of the reference product. […]
Encouraging objective response rate of 52.4% was seen with ifinatamab deruxtecan in heavily pretreated patients IDeate-01 phase 2 trial currently enrolling patients with extensive-stage small […]
An objective response rate of 29.8% was observed with patritumab deruxtecan in heavily pretreated patients BLA submission in U.S. planned for the second half of […]
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab with or without chemotherapy demonstrated objective response rates of 77% and 50% and disease control rates of […]
Medical professionals and social organizations call for increased awareness of pneumococcal threat and strengthened preventative measures among high-risk individuals HONG KONG SAR – Media OutReach […]
Copyright © 2026 | Miscw.com